Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study

References

• Sachs GS. Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 2003; 23: S2–S8
   PubMed Web of Science ®Google Scholar
• Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990; 26: 409–27
   PubMedGoogle Scholar
• Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 277–84
   PubMed Web of Science ®Google Scholar
• Mensink GJR, Slooff CJ. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand 2004; 109: 405–19
   PubMed Web of Science ®Google Scholar
• McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003; 5: 20–35
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol 2004; 11: e218–e226
   PubMedGoogle Scholar
• Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004; 65: 21–4
   PubMed Web of Science ®Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176–80
   PubMed Web of Science ®Google Scholar
• Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol Clin Exp 2004; 19: 41–5
   PubMed Web of Science ®Google Scholar
• Hirschfeld RMA, Keck PE, Kramer M, Canuso C, Eerdekens M, Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65
   PubMed Web of Science ®Google Scholar
• Yatham LN, Binder C, Kusumakar V, Riccardelli R. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. Int Clin Psychopharmacol 2004; 19: 103–9
   PubMed Web of Science ®Google Scholar
• Yatham LN, Binder C, Riccardelli R, Leblanc J, Connolly M, Kusumakar V. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003; 18: 227–35
   PubMed Web of Science ®Google Scholar
• Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 2004; 65: 707–14
   PubMed Web of Science ®Google Scholar
• Conte G, Parrinello G. Risperidone versus haloperidol in the long-term treatment of bipolar patients with psychotic symptoms: a naturalistic study. European Conference of Neuropsychopharmacology, 2003.
   Google Scholar
• Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818–25
   PubMed Web of Science ®Google Scholar
• Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001; 67: 213–19
   PubMed Web of Science ®Google Scholar
• Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121–30
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. No. (ADM) . Rockville: Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. pp 218–20.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538–46
   PubMed Web of Science ®Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233
   Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429–35
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Chue P. Risperidone long-acting injection. Expert Rev Neurotherapeutics 2003; 3: 435–46
   PubMedGoogle Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–32
   PubMed Web of Science ®Google Scholar
• Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8: 175–81
   PubMed Web of Science ®Google Scholar